Media Releases

Te Aho o Te Kahu has been in regular contact with the District Health Boards to ensure essential cancer treatment continues at COVID-19 Alert Levels 3 and 4

Te Aho o Te Kahu, the Cancer Control Agency, fully supports the initiatives in the Proposals for Smokefree Aotearoa 2025 Action Plan.

Lung cancer is the leading cause of cancer death in Aotearoa, New Zealand. It is also a disease which contributes to inequities within the health system, with mortality rates three to four times higher for Māori than non-Māori.

We have many world class aspects of cancer control in New Zealand, and the cancer workforce is full of highly committed and talented people, but if we are to improve our cancer survival rates compared to similar countries, focused action is needed

As Te Aho o Te Kahu enters its second year, it will continue to keep all those affected by cancer as its focus, Professor Sarfati says.

Improvements must be made to decrease the high number New Zealanders dying of lung cancer, Te Aho o Te Kahu Chief Executive Professor Diana Sarfati says.

New Zealand patients with neuroendocrine cancers (NETs) who have been unable to access regular treatment in Australia due to COVID-19 will now be treated in Auckland thanks to an interim arrangement.

A report released today by Te Aho o Te Kahu, the independent Cancer Control Agency, shows a ‘catch up’ in cancer diagnoses is underway.

For those already diagnosed with cancer, treatment largely continued through the COVID-19 lockdown, according to analysis carried out by the Cancer Control Agency.

Te Aho o Te Kahu is excited to announce that Paediatric Oncologist and Neuro-Oncologist, Dr Stephen Laughton, has been appointed as the new Clinical Lead for the National Child Cancer Network (NCCN)